Kenji Nakano

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 18

Top Topics

Squamous Cell Carcinoma

Tyrosine Kinase

Metastatic Colorectal Cancer

Top Venues

International journal of molecular sciences

Endocrine journal

Oxford medical case reports

Molecular biomedicine

This page only lists publications with an associated author ORCID identifier.

Publications

Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine journal 71 (4) (2024)
Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine journal 71 (4) (2024)
Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine journal (2024)
Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine journal 71 (4) (2024)
Kenji Nakano
The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results. International journal of molecular sciences 24 (23) (2023)
Kenji Nakano
Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy. Japanese journal of clinical oncology (2023)
Kenji Nakano
Challenges of Systemic Therapy Investigations for Bone Sarcomas. International journal of molecular sciences 23 (7) (2022)
Akihiro Ohmoto, Yu Fujiwara, Nobuyuki Horita, Kenji Nakano, Shunji Takahashi
Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis. Discover. Oncology 13 (1) (2022)
Shunji Takahashi, Yutaka Fujiwara, Kenji Nakano, Toshio Shimizu, Junichi Tomomatsu, Takafumi Koyama, Mariko Ogura, Masaya Tachibana, Yasuyuki Kakurai, Tomonari Yamashita, Sakura Sakajiri, Noboru Yamamoto
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. Cancer science 112 (6) (2021)
Kenji Nakano
Progress of molecular targeted therapy for head and neck cancer in clinical aspects. Molecular biomedicine 2 (1) (2021)
Yasuyoshi Sato, Kenji Nakano, Xiaofei Wang, Naoki Fukuda, Tetsuya Urasaki, Akihiro Ohmoto, Naomi Hayashi, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu, Masanori Saito, Yusuke Minami, Keiko Hayakawa, Yuki Funauchi, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Shunji Takahashi
Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. Cancers 13 (24) (2021)
Kenji Nakano, Masatoshi Nishizawa, Naoki Fukuda, Tetsuya Urasaki, Xiaofei Wang, Hiroki Mitani, Shunji Takahashi
Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis. Oxford medical case reports 2020 (4) (2020)
Naoki Fukuda, Mayu Yunokawa, Yu Fujiwara, Xiaofei Wang, Akihiro Ohmoto, Naomi Hayashi, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. Cancer reports (Hoboken, N.J.) 4 (2) (2020)
Kenji Nakano, Keisuke Ae, Seiichi Matsumoto, Shunji Takahashi
The VAC regimen for adult rhabdomyosarcoma: Differences between adolescent/young adult and older patients. Asia-Pacific journal of clinical oncology 16 (2) (2019)
Kenji Nakano, Akira Seto, Toru Sasaki, Wataru Shimbashi, Hirofumi Fukushima, Hiroyuki Yonekawa, Hiroki Mitani, Shunji Takahashi
Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab. Head & neck 41 (8) (2019)
Kenji Nakano, Yuki Funauchi, Keiko Hayakawa, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Shunji Takahashi
Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders. Journal of clinical medicine 8 (1) (2019)
Kenji Nakano, Shunji Takahashi
Translocation-Related Sarcomas. International journal of molecular sciences 19 (12) (2018)
Kenji Nakano, Shunji Takahashi
Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. International journal of molecular sciences 19 (3) (2018)